Zymeworks News

News

0

Ticker

ZYME

ISIN

US98985Y1082

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Zymeworks Eulerpool News

11/21/2024, 9:33:56 PM

Ziihera: Meilenstein in der Krebsbehandlung durchbricht die FDA-Schranken

10/22/2024, 10:26:30 AM

Zymeworks startet klinische Phase-I-Studie für innovatives Krebsmedikament ZW171

Zymeworks Stock News

Zymeworks is being monitored by journalists and investors worldwide. We gather the latest Zymeworks news here.

September 18·
SeekingAlpha
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow
February 12·
Yahoo
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
January 22·
SeekingAlpha
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
December 17·
Benzinga
Truist Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $40
December 3·
Benzinga
Citizens Initiates Coverage On Zymeworks with Market Outperform Rating, Announces Price Target of $32
November 21·
SeekingAlpha
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA
November 20·
SeekingAlpha
Zymeworks Inc. 2025 Q3 - Results - Earnings Call Presentation
November 19·
SeekingAlpha
Zymeworks: A Lot Of Moving Parts
November 19·
Benzinga
Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $25
November 19·
Benzinga
Stifel Maintains Buy on Zymeworks, Raises Price Target to $40
November 17·
SeekingAlpha
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
November 17·
SeekingAlpha
Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity
November 17·
Benzinga
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
November 17·
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 17·
Benzinga
Zymeworks And Partners Report Statistically Significant And Clinically Meaningful Improvements Across PFS OS ORR And DoR In HERIZON GEA 01
November 7·
Benzinga
Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $17
November 7·
SeekingAlpha
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
November 4·
Yahoo
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
November 4·
Yahoo
A Look at Zymeworks (ZYME) Valuation After 50% Share Price Rally Over 3 Months
October 30·
Yahoo
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zymeworks Stock Press Releases

Zymeworks regularly publishes news on the company's website that are relevant for investors.

January 25•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conferences
January 4•
Zymeworks
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
December 21•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conference
December 19•
Zymeworks
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
December 14•
Zymeworks
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
December 9•
Zymeworks
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
December 5•
Zymeworks
Zymeworks to Transfer Stock Listing to Nasdaq
November 29•
Zymeworks
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
November 22•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conference
November 21•
Zymeworks
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
November 8•
Zymeworks
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
October 20•
Zymeworks
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
October 18•
Zymeworks
Zymeworks to Host Third Quarter Results Conference Call
October 13•
Zymeworks
Zymeworks Completes Plan to Become Delaware Corporation
October 7•
Zymeworks
Zymeworks Announces Results of Special Meeting
October 4•
Zymeworks
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
October 3•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
September 26•
Zymeworks
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
September 16•
Zymeworks
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
September 12•
Zymeworks
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
September 8•
Zymeworks
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
September 4•
Zymeworks
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
August 4•
Zymeworks
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 1•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conferences
July 25•
Zymeworks
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
July 22•
Zymeworks
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
July 21•
Zymeworks
Zymeworks to Host Second Quarter Results Conference Call
July 15•
Zymeworks
Zymeworks Announces Plan to Become a Delaware Corporation
June 27•
Zymeworks
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
June 10•
Zymeworks
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company

Zymeworks News 2026

This page contains all current news, analysis and press releases for Zymeworks stock (ZYME, ISIN: US98985Y1082). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Zymeworks.